|
Feb 13
|
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025
|
|
Feb 13
|
BridgeBio price target raised to $49 from $48 at Scotiabank
|
|
Feb 12
|
EC grants marketing authorisation to BridgeBio’s ATTR-CM treatment
|
|
Feb 11
|
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
|
|
Feb 11
|
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK
|
|
Feb 8
|
Why BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to Analysts
|
|
Jan 15
|
Is BridgeBio Pharma, Inc. (BBIO) Among Tuesday’s Top Gainers?
|
|
Jan 14
|
BridgeBio Pharma Stock Earns 87 RS Rating
|
|
Jan 14
|
Why BridgeBio Pharma (BBIO) Led the Monday Upsurge?
|
|
Oct 4
|
3 Top Stocks That Could Still Rocket Higher in 2024
|
|
Oct 3
|
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
|
|
Oct 1
|
5 FDA decisions to watch in the fourth quarter
|
|
Sep 30
|
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
|
|
Sep 30
|
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
|
|
Sep 27
|
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
|
|
Aug 30
|
Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug
|
|
Aug 30
|
Why Is BridgeBio Pharma Stock Trading Higher On Friday?
|
|
Aug 30
|
BridgeBio Pharma Reports Positive Additional Data From Phase 3 Study of Acoramidis; Shares Rise
|
|
Aug 30
|
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
|
|
Aug 29
|
BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
|